Tags

Type your tag names separated by a space and hit enter

Drug treatment of obesity: current status and future prospects.
Eur J Intern Med. 2015 Mar; 26(2):89-94.EJ

Abstract

Obesity is a growing epidemic and a major contributor to the global burden of disease. Obesity strains the healthcare systems and has profound economic and psychosocial consequences. Historically, pharmacotherapy for obesity has witnessed the rise and fall of several promising drug candidates that had to be eventually withdrawn due to unacceptable safety concerns. Currently four drugs are approved for chronic weight management in obese adults: orlistat, lorcaserin, phentermine/topiramate extended release and naltrexone/bupropion extended release. While lorcaserin and phentermine/topiramate were approved by US Food and Drug Administration (FDA) in 2012, after a gap of 13 years following the licensing of orlistat, naltrexone/bupropion has been recently approved in 2014. This review provides a brief overview of these current therapeutic interventions available for management of obesity along with the evidence of their safety and efficacy. Additionally, several novel monotherapies as well as combination products are undergoing evaluation in various stages of clinical development. These therapies if proven successful will strengthen the existing armamentarium of antiobesity drugs and will be critical to combat the global public health crisis of obesity and its associated co-morbidities.

Authors+Show Affiliations

Dept. of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address: drashishkakkar@gmail.com.Dept. of Community Medicine, Lady Hardinge Medical College, New Delhi, India. Electronic address: drnehadahiya@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25634851

Citation

Kakkar, Ashish Kumar, and Neha Dahiya. "Drug Treatment of Obesity: Current Status and Future Prospects." European Journal of Internal Medicine, vol. 26, no. 2, 2015, pp. 89-94.
Kakkar AK, Dahiya N. Drug treatment of obesity: current status and future prospects. Eur J Intern Med. 2015;26(2):89-94.
Kakkar, A. K., & Dahiya, N. (2015). Drug treatment of obesity: current status and future prospects. European Journal of Internal Medicine, 26(2), 89-94. https://doi.org/10.1016/j.ejim.2015.01.005
Kakkar AK, Dahiya N. Drug Treatment of Obesity: Current Status and Future Prospects. Eur J Intern Med. 2015;26(2):89-94. PubMed PMID: 25634851.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug treatment of obesity: current status and future prospects. AU - Kakkar,Ashish Kumar, AU - Dahiya,Neha, Y1 - 2015/01/26/ PY - 2014/12/15/received PY - 2015/01/14/revised PY - 2015/01/19/accepted PY - 2015/1/31/entrez PY - 2015/1/31/pubmed PY - 2015/12/15/medline KW - Antiobesity agents KW - Lorcaserin KW - Naltrexone/bupropion extended release KW - Obesity KW - Orlistat KW - Phentermine/topiramate extended-release SP - 89 EP - 94 JF - European journal of internal medicine JO - Eur. J. Intern. Med. VL - 26 IS - 2 N2 - Obesity is a growing epidemic and a major contributor to the global burden of disease. Obesity strains the healthcare systems and has profound economic and psychosocial consequences. Historically, pharmacotherapy for obesity has witnessed the rise and fall of several promising drug candidates that had to be eventually withdrawn due to unacceptable safety concerns. Currently four drugs are approved for chronic weight management in obese adults: orlistat, lorcaserin, phentermine/topiramate extended release and naltrexone/bupropion extended release. While lorcaserin and phentermine/topiramate were approved by US Food and Drug Administration (FDA) in 2012, after a gap of 13 years following the licensing of orlistat, naltrexone/bupropion has been recently approved in 2014. This review provides a brief overview of these current therapeutic interventions available for management of obesity along with the evidence of their safety and efficacy. Additionally, several novel monotherapies as well as combination products are undergoing evaluation in various stages of clinical development. These therapies if proven successful will strengthen the existing armamentarium of antiobesity drugs and will be critical to combat the global public health crisis of obesity and its associated co-morbidities. SN - 1879-0828 UR - https://www.unboundmedicine.com/medline/citation/25634851/Drug_treatment_of_obesity:_current_status_and_future_prospects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0953-6205(15)00024-2 DB - PRIME DP - Unbound Medicine ER -